KeyBanc has reiterated an Overweight recommendation on Revvity Inc (NYSE: RVTY), keeping a price target of $125.00 - approximately 16.7% above the stock's referenced price of $107.09. The broker's stance is consistent with a broader analyst consensus that sees an average upside near 11% for the name.
KeyBanc maintained its constructive view despite Revvity's fiscal 2026 guidance for organic growth of 2-3%, a pace the firm characterizes as conservative relative to some industry peers that have projected growth beginning at 3%. Paul Knight, the KeyBanc analyst covering the account, highlighted that the guidance looks subdued versus competitors such as Danaher and Thermo Fisher Scientific.
Still, KeyBanc pointed to concrete signs of strengthening within Revvity's operations. The company reported organic growth of 4% in the fourth quarter of 2025, and its diagnostics business delivered particularly strong results with 7% organic growth in Q4 2025 despite reported headwinds in the Chinese market. Those quarterly figures factored into KeyBanc's view that Revvity may be positioned to capture upside if broader market conditions improve.
The analyst note also emphasized corporate actions intended to lift earnings per share. KeyBanc flagged the company's plan to accelerate share repurchases as a lever to boost EPS over time, and observed that Revvity's stock currently trades at a discount to peers on an enterprise value to EBITDA basis - implying potential valuation catch-up if execution and market dynamics align.
On the earnings front, Revvity disclosed fourth-quarter 2025 results that beat consensus on both the bottom and top lines. Adjusted earnings per share came in at $1.70 versus an expected $1.55, and revenue reached $772 million compared with analysts' projections of $758.53 million. Despite the beats, the stock moved lower in pre-market trading following the release.
There were no recent public announcements regarding mergers or acquisitions by Revvity, and analyst firms have not issued fresh upgrades or downgrades for the company in the immediate aftermath of the results. These developments collectively underline the company's most recent financial performance and how market participants are pricing that information.
Context and outlook
KeyBanc's reiteration reflects a view that while near-term organic growth guidance is modest, tangible momentum in the December quarter and financial engineering through buybacks create a pathway to improved shareholder returns. The balance between conservative forward guidance and recent outperformance is central to the firm's unchanged Overweight rating.